Literature DB >> 35597779

mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Shugang Qin1, Xiaoshan Tang1, Yuting Chen1, Kepan Chen1, Na Fan1, Wen Xiao1, Qian Zheng1, Guohong Li1, Yuqing Teng1, Min Wu2, Xiangrong Song3.   

Abstract

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide range of incurable diseases. Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human body by introducing mRNA as a vaccine or therapeutic agent. This represents a rising precision medicine field with great promise for preventing and treating many intractable or genetic diseases. In addition, in vitro transcribed mRNA has achieved programmed production, which is more effective, faster in design and production, as well as more flexible and cost-effective than conventional approaches that may offer. Based on these extraordinary advantages, mRNA vaccines have the characteristics of the swiftest response to large-scale outbreaks of infectious diseases, such as the currently devastating pandemic COVID-19. It has always been the scientists' desire to improve the stability, immunogenicity, translation efficiency, and delivery system to achieve efficient and safe delivery of mRNA. Excitingly, these scientific dreams have gradually been realized with the rapid, amazing achievements of molecular biology, RNA technology, vaccinology, and nanotechnology. In this review, we comprehensively describe mRNA-based therapeutics, including their principles, manufacture, application, effects, and shortcomings. We also highlight the importance of mRNA optimization and delivery systems in successful mRNA therapeutics and discuss the key challenges and opportunities in developing these tools into powerful and versatile tools to combat many genetic, infectious, cancer, and other refractory diseases.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35597779      PMCID: PMC9123296          DOI: 10.1038/s41392-022-01007-w

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  561 in total

1.  A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.

Authors:  Yanina Jansen; Vibeke Kruse; Jurgen Corthals; Kelly Schats; Pieter-Jan van Dam; Teofila Seremet; Carlo Heirman; Lieve Brochez; Mark Kockx; Kris Thielemans; Bart Neyns
Journal:  Cancer Immunol Immunother       Date:  2020-06-26       Impact factor: 6.968

2.  Trinucleotide Cap Analogue Bearing a Locked Nucleic Acid Moiety: Synthesis, mRNA Modification, and Translation for Therapeutic Applications.

Authors:  Annamalai Senthilvelan; Tyson Vonderfecht; Muthian Shanmugasundaram; Indra Pal; Jason Potter; Anilkumar R Kore
Journal:  Org Lett       Date:  2021-05-19       Impact factor: 6.005

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 4.  Dendritic cells in cancer immunology and immunotherapy.

Authors:  Stefanie K Wculek; Francisco J Cueto; Adriana M Mujal; Ignacio Melero; Matthew F Krummel; David Sancho
Journal:  Nat Rev Immunol       Date:  2019-08-29       Impact factor: 53.106

5.  Systemic delivery of factor IX messenger RNA for protein replacement therapy.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Kiyoshi Tachikawa; Pattraranee Limphong; Jerel B Vega; Priya P Karmali; Pad Chivukula; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-15       Impact factor: 11.205

6.  Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety.

Authors:  Kevin Van der Jeught; Stefaan De Koker; Lukasz Bialkowski; Carlo Heirman; Patrick Tjok Joe; Federico Perche; Sarah Maenhout; Sanne Bevers; Katrijn Broos; Kim Deswarte; Virginie Malard; Hamida Hammad; Patrick Baril; Thierry Benvegnu; Paul-Alain Jaffrès; Sander A A Kooijmans; Raymond Schiffelers; Stefan Lienenklaus; Patrick Midoux; Chantal Pichon; Karine Breckpot; Kris Thielemans
Journal:  ACS Nano       Date:  2018-10-01       Impact factor: 15.881

7.  Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.

Authors:  Margaret M Billingsley; Nathan Singh; Pranali Ravikumar; Rui Zhang; Carl H June; Michael J Mitchell
Journal:  Nano Lett       Date:  2020-02-05       Impact factor: 11.189

Review 8.  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.

Authors:  Margaret A Liu
Journal:  Vaccines (Basel)       Date:  2019-04-24

9.  Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.

Authors:  Steve Boudewijns; Martine Bloemendal; Nienke de Haas; Harm Westdorp; Kalijn F Bol; Gerty Schreibelt; Erik H J G Aarntzen; W Joost Lesterhuis; Mark A J Gorris; Alexandra Croockewit; Lieke L van der Woude; Michelle M van Rossum; Marieke Welzen; Anna de Goede; Stanleyson V Hato; Winette T A van der Graaf; Cornelis J A Punt; Rutger H T Koornstra; Winald R Gerritsen; Carl G Figdor; I Jolanda M de Vries
Journal:  Cancer Immunol Immunother       Date:  2020-01-24       Impact factor: 6.968

10.  SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.

Authors:  Nanda Kishore Routhu; Narayanaiah Cheedarla; Venkata Satish Bollimpelli; Sailaja Gangadhara; Venkata Viswanadh Edara; Lilin Lai; Anusmita Sahoo; Ayalnesh Shiferaw; Tiffany M Styles; Katharine Floyd; Stephanie Fischinger; Caroline Atyeo; Sally A Shin; Sanjeev Gumber; Shannon Kirejczyk; Kenneth H Dinnon; Pei-Yong Shi; Vineet D Menachery; Mark Tomai; Christopher B Fox; Galit Alter; Thomas H Vanderford; Lisa Gralinski; Mehul S Suthar; Rama Rao Amara
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.